LONGO, FRANCESCO
 Distribuzione geografica
Continente #
NA - Nord America 656
EU - Europa 314
AS - Asia 138
OC - Oceania 4
AF - Africa 1
SA - Sud America 1
Totale 1.114
Nazione #
US - Stati Uniti d'America 654
PL - Polonia 144
CN - Cina 55
IT - Italia 44
SG - Singapore 39
TR - Turchia 26
DE - Germania 24
GB - Regno Unito 23
UA - Ucraina 21
SE - Svezia 16
BE - Belgio 11
ID - Indonesia 11
AT - Austria 10
FI - Finlandia 9
FR - Francia 7
AU - Australia 4
VN - Vietnam 3
CA - Canada 2
NO - Norvegia 2
AL - Albania 1
EC - Ecuador 1
HK - Hong Kong 1
HR - Croazia 1
IQ - Iraq 1
JP - Giappone 1
MA - Marocco 1
RO - Romania 1
TW - Taiwan 1
Totale 1.114
Città #
Warsaw 144
Woodbridge 88
Ann Arbor 84
Fairfield 82
Chandler 50
Santa Clara 40
Ashburn 39
Houston 37
Singapore 34
Jacksonville 31
Seattle 31
Wilmington 30
Cambridge 25
Beijing 21
Izmir 17
Ferrara 16
Brussels 11
Jakarta 11
Vienna 10
Bremen 9
Nanjing 9
Princeton 9
Shanghai 9
Boardman 7
Milan 6
San Diego 6
Cagliari 4
Cordignano 4
Los Angeles 4
Changsha 3
Dong Ket 3
Falls Church 3
Helsinki 3
Redwood City 3
Auburn University 2
Des Moines 2
Göteborg 2
London 2
Melbourne 2
New York 2
Norwalk 2
Shenyang 2
Tappahannock 2
Tianjin 2
Toronto 2
Washington 2
Bloomsbury 1
Bordeaux 1
Changchun 1
Chicago 1
Chiswick 1
Edinburgh 1
Erbil 1
Falkenstein 1
Hebei 1
Indiana 1
Jiaxing 1
Jinan 1
Kunming 1
Leawood 1
Legnago 1
Lucca 1
Mountain View 1
Nanchang 1
Orange 1
Paris 1
Quito 1
Stockholm 1
Taipei 1
Tirana 1
Tokyo 1
Zagreb 1
Totale 933
Nome #
Altered motor phenotype and dopamine transmission associated with mutations of the parkinsonian gene LRRK2 215
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 160
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 155
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 131
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. 120
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 119
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 88
null 77
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter 51
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex 25
Totale 1.141
Categoria #
all - tutte 5.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.093


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020160 0 0 0 0 0 26 22 26 24 28 21 13
2020/2021185 14 23 7 16 10 19 6 24 9 27 20 10
2021/2022114 2 7 10 3 8 20 7 8 7 5 12 25
2022/2023138 10 14 11 12 30 16 8 11 12 0 9 5
2023/202473 13 5 4 0 6 8 3 11 2 2 1 18
2024/2025102 5 6 29 10 24 28 0 0 0 0 0 0
Totale 1.141